Incyte (INCY) Total Current Liabilities (2010 - 2026)
Incyte (INCY) reported Total Current Liabilities of $1.5 billion for Q1 2026, down 13.41% on a YoY basis from $1.7 billion in Q1 2025, and down 1.68% quarter-over-quarter from $1.5 billion in Q4 2025.
Incyte (INCY) Total Current Liabilities (2010 - 2026) Analysis & Trends
Incyte has reported Total Current Liabilities for 17 years, with the latest figure at $1.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 13.41% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 13.41% YoY), and the FY2025 full-year result was $1.5 billion, down 7.72% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $1.5 billion, down from $1.5 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $1.7 billion in Q1 2025, with the low at $886.2 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 42.04% — and 2026, when it slipped 13.41%.
- Incyte's Total Current Liabilities stood at $1.2 billion in 2022, then gained by 7.2% to $1.2 billion in 2023, then soared by 32.37% to $1.6 billion in 2024, then fell by 7.72% to $1.5 billion in 2025, then declined by 1.68% to $1.5 billion in 2026.
- The last three Total Current Liabilities figures came in at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 1.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.34 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.72 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.34 Bn |
| Mar 31, 2024 | 1.40 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 1.01 Bn |
| Jun 30, 2022 | 926.67 Mn |
| Mar 31, 2022 | 886.16 Mn |
| Dec 31, 2021 | 854.31 Mn |
| Sep 30, 2021 | 742.71 Mn |
| Jun 30, 2021 | 660.32 Mn |